Answers are grounded in this paper and cite their sources.
In patients with advanced IDH1-mutated relapsed or refractory AML, ivosidenib at a dose of 500 mg daily was associated with a low frequency of grade 3 or higher treatment-related adverse events and with transfusion independence, durable remissions, and molecular remissions in some patients with complete remission. (Funded by Agios Pharmaceuticals; ClinicalTrials.gov number, NCT02074839 .).
No takes yet. Share an insight, caveat, or question.
DiNardo et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: